Hormone therapy in the menopause and breast cancer risk - A review

Maturitas

Volumn 23, Issue 2, 1996, Pages 241-246

  Ewertz, Marianne ^a  

^a INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

Author keywords

Breast cancer risk; Hormone therapy; Menopause

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; BREAST CANCER; CANCER RISK; CONFERENCE PAPER; DRUG SAFETY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

EID: 0029952504     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/0378-5122(95)00977-9     Document Type: Conference Paper

References (32)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993; 54: 594-606.
2. Miller AB, Bulbrooke RD. UICC Multidisciplinary project on breast cancer: the epidemiology, aetiology and prevention of breast cancer. Int J Cancer 1986; 37: 173-177.
3. Harris R, Laws A. Reddy V et al. Are women using postmenopausal estrogens ? A community survey. Am J Public Health 1990; 80: 1266-1268.
4. Barlow DH, Grosset KA, Hart H, Hart DM. A study of the experience of Glasgow women in the climacteric ages. Br J Obstet Gynaecol 1989; 96: 1192-1197.
5. Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 1988; 42: 832-838.
6. Ewertz M. Risk from age, race and social class. In: Stoll BA, ed. Reducing breast cancer risk in women. Dordrecht: Kluwer Academic Publishers 1995; 41-45.
7. Kelsey JL, Hildreth NG. Breast and Gynecologic Cancer Epidemiology. Florida: CRC Press Boca Raton, 1983.
8. Cauley JA, Gutai JP, Kuller LH, LeDonne D, Powell LH. The epidemiology of serum sex hormones in postmenopausal women. Am J Epidemiol 1989; 129: 1120-1131.
9. Secreto G, Toniolo P. Pisani P et al. Androgens and breast cancer in premenopausal women. Cancer Research 1989; 49: 471-476.
10. Secreto G, Toniolo P, Berrino F et al. Serum and urinary androgens and risk of breast cancer in postmenopausal women. Cancer Research 1991; 51: 2572-2576.
11. Thijssen JHH, Blankenstein MA. Endogenous oestrogens and androgens in normal and malignant endometrial and mammary tissues. Eur J Cancer Clin Oncol 1989; 25: 1953-1959.
12. Committee on the Relationship between Oral Contraceptives and Breast Cancer, Institute of Medicine, Division of Health Promotion and Disease Prevention. Oral contraceptives and breast cancer. Washington, DC: National Academy Press, 1991.
13. Committee on Safety of Medicines. Carcinogenicity test of oral contraceptives. London: Her Majesty's Stationary Office, 1972.
14. Armstrong BK. Oestrogen therapy after the menopause boon or bane ? Med J Aust 1988; 148: 213-214.
15. Steinberg KK, Thacker SB, Smith J, Stroup DF, Zack MM, Flanders WD, Berkelman RL. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991; 265: 1985-1990.
16. Sillero-Arenas M, Delgado-Rodriguez M, Rodrigues-Canteras R, Bueno-Cavanillas A, Galvez-Vargas R. Menopausal hormone replacement theray and breast cancer: a meta-analysis. Obstet Gynecol 1992; 79: 286-294.
17. Grady D, Rubin SM, Petitti DB et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Int Med 1992; 117: 1016-1037.
18. Dupont WD, Page DL. An overview of the effect of oestrogen replacement therapy on breast cancer risk. In: Mann RD, ed. Hormone replacement therapy and breast cancer risk. London: Parthenon Publishing Group, 1992; 79-92.
19. Brinton LA, Schairer C. Estrogen replacement therapy and breast cancer risk. Epidemiologic Reviews 1993; 15: 66-79.
20. Colditz GA, Hankinsom SE, Hunter DJ et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589-1593.
21. Schairer C, Byrne C, Keyl PM, Brinton LA, Sturgeon SR, Hoover RN. Menopausal estogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes and Control 1994; 5: 491-500.
22. Brinton LA, Hoover R, Fraumeni JF, Jr. Menopausal oestrogens and breast cancer risk: an expanded study. Br J Cancer 1986; 54:825-832.
23. McDonald JA, Weiss NS, Daling JR et al. Menopausal estrogen use and the risk of breast cancer. Breast Cancer Res Treat 1986; 7: 193-199.
24. Nomura AMY, Kolonel LN, Hirohata T et al. The association of replacement estrogens with breast cancer. Int J Cancer 1986; 37: 49-53.
25. Hunt K, Vessey M, McPherson K et al. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol 1987; 94: 620-635.
26. Wingo PA, Layde PM, Lee NC et al. The risk of breast cancer in postmenopausal women who have used estrogen replacement therapy. JAMA 1987; 257: 209-215.
27. Bergkvist L, Adami H-O, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med; 1989; 321: 293-297.
28. Mills PK, Beeson L, Phillips RL et al. Prospective study of exogenous hormone use and breast cancer in Seventh-Day Adventists. Cancer 1989; 64: 591-597.
29. Kaufman DW, Palmer JR, de Mouzon J et al. Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study. Am J Epidemiol 1991; 134: 1375-1385.
30. Palmer JR, Rosenberg L, Clarke EA et al. Breast cancer risk after estrogen replacement therapy: results from the Toronto Breast Cancer Study. Am J Epidemiol 1991; 134: 1386-1395.
31. Yang CP, Daling JR, Band PR et al. Noncontraceptive hormone use and risk of breast cancer. Cancer Causes and Control 1992; 3: 475-479.
32. Stanford JL, Thomas DB. Exogenous progestins and breast cancer. Epidemiol Rev 1993; 15: 98-107.